Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease - Top-Institutions - MDSpire

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

  • By

  • Katie Binley, PhD

  • May 1, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute (University of Miami Health System)
    Bascom Palmer Eye Institute (University of Miami Health System)

    Miami, Florida

    Key Differentiators

    • Ophthalmology
    • Retinal Disease
    • Gene Therapy

  • #2

    Wilmer Eye Institute, Johns Hopkins Medicine
    Wilmer Eye Institute, Johns Hopkins Medicine

    Baltimore, Maryland

    Key Differentiators

    • Ophthalmology
    • Gene Therapy
    • Regenerative Medicine

  • #3

    Institute of Molecular and Clinical Ophthalmology Basel
    Institute of Molecular and Clinical Ophthalmology Basel

    Basel, Switzerland

    Key Differentiators

    • Ophthalmology
    • Gene Editing

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Ophthalmology
    • Retinal Disease

  • #5

    Wills Eye Hospital
    Wills Eye Hospital

    Philadelphia, Pennsylvania

    Key Differentiators

    • Ophthalmology
    • Retinal Research

Original Source(s)

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

  • by Katie Binley, PhD

  • May 1, 2026

Related Content

Evaluation of Laser Doppler Holography for Assessing Choroidal Blood Flow: A Comprehensive Review of Technical Features, Validation Research, and Clinical Uses

Supplying Ocular Nutritional Supplements

Supplying ocular nutritional supplements (ONS) is a way to deepen patient trust and improve their visual outcomes, with the byproduct a new revenue stream. This is the theme of this issue of Optometric Management. 

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it.